Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
Braz J Med Biol Res
; 15(6): 389-94, 1982 Dec.
Article
em En
| MEDLINE
| ID: mdl-6135468
Tardive dyskinesia is a syndrome of involuntary movements that develops during or following long-term neuroleptic treatment. Current treatment of tardive dyskinesia is unsatisfactory. Neuroleptics can reduce the syndrome, but the underlying pathogenetic process is probably aggravated during treatment. The use of these drugs is necessary, however, when the patient simultaneously exhibits intense psychotic and dyskinetic symptoms. In this controlled study, 8 patients were treated with a beta-blocker drug, oxprenolol, as a slow-release preparation that was administered in increasing doses up to 640 mg per day for one month. We conclude that this drug can ameliorate both the psychotic features of schizophrenics and their tardive dyskinetic movements without producing significant side-effects.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Oxprenolol
/
Esquizofrenia
/
Discinesia Induzida por Medicamentos
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Braz J Med Biol Res
Ano de publicação:
1982
Tipo de documento:
Article
País de publicação:
Brasil